Daniel Stetson
AstraZeneca (United States) · 74 works · 4,528 citations · h-index 18
Top works
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
- Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
- Analysis of Ras-Induced Overproliferation in Drosophila Hemocytes
- Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
- Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
- Orthogonal Comparison of Four Plasma NGS Tests With Tumor Suggests Technical Factors are a Major Source of Assay Discordance
- Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology
- Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer
- Exon 16–Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M–Positive Non–Small Cell Lung Cancer
- Abstract LB-249: Examination of analytical factors impacting concordance of plasma-tumor testing by next-generation sequencing (NGS)
- Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer
- Next-Generation Molecular Residual Disease Assays: Do We Have the Tools to Evaluate Them Properly?
- Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions
- Effects of intermittent ischemia on contractile properties and myosin isoforms of skeletal muscle
- Generation of stable PDX derived cell lines using conditional reprogramming
- Prioritisation of structural variant calls in cancer genomes
- Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health
- Molecular landscape of osimertinib resistance revealed by targeted panel sequencing and patient-derived cancer models in non-small cell lung cancer patients
- Serial postoperative ctDNA monitoring of breast cancer recurrence.